Overview

Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease

Status:
Not yet recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This study seeks to bridge these technologies and obtain data regarding the safety and efficacy of image guided percutaneous needle injection of expanded autologous bone marrow derived mesenchymal stem cells to symptomatic degenerated intervertebral discs in humans. The primary outcome will be to assess the safety and efficacy and monitor for adverse events.
Phase:
Early Phase 1
Details
Lead Sponsor:
Salim M Hayek
Treatments:
Pharmaceutical Solutions